medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2023, Number 09

<< Back Next >>

Ginecol Obstet Mex 2023; 91 (09)

Chorea as the first clinical manifestation of systemic lupus erythematosus without antiphospholipid syndrome: case report and literature review

Trujillo IC, Rodríguez VJC, Becerril GANG, Barrera GAG, González MJ, Reséndiz OAk

Language: Spanish
References: 35
Page: 687-697
PDF size: 570.04 Kb.


ABSTRACT

Background: Chorea gravidarum is a rare condition characterised by irregular, unpredictable, spontaneous movements of short duration, changing location without defined sequence, and with the peculiarity of being involuntary. Currently, its incidence is estimated at 1 case per 2275 pregnancies.
Clinical case: Patient aged 30 years, 45 kg, height 1.65 m, BMI 16.5, blood pressure 110-78 mmHg, heart rate 136 bpm, respiratory rate 19 rpm, oxygen saturation 98%. She started with choreic movements at 12 weeks of pregnancy and titration of antinuclear antibodies 1:320, anti-DNA antibodies 150 IU/mL, C3 at 126 mg/dL and C4 at 31 mg/ dL. The diagnosis of systemic lupus erythematosus was established based on EULAR/ ACR criteria. At 32 weeks she had threatened preterm labour and progression, despite utero-inhibition, preeclampsia with severity criteria and neuropsychiatric manifestations with exacerbation of choreic movements. MRI reported no pathological findings and secondary antiphospholipid antibody syndrome was ruled out. After termination of pregnancy the involuntary movements characteristic of chorea gravidarum subsided.
Conclusion: Prenatal monitoring in the first trimester is essential for a favourable patient outcome; early initiation of immunotherapy is crucial for perinatal outcomes as it decreases associated morbidity and mortality. Chorea is a disabling clinical manifestation, hence the importance of identifying its cause and initiating timely treatment.


REFERENCES

  1. Willson P, Preece Aa. Chorea gravidarum: A statisticalstudy of 951 collected Cases, 846 From the Literature and105 previously unreported. Arch Intern Med 1932; 49 (3):471-533. doi:10.1001/archinte.1932.00150100128011

  2. Mastorodemos V, Mamoulaki M, Kritikos H, Plaitakis A,Boumpas DT. Central nervous system involvement asthe presenting manifestation of autoimmune rheumaticdiseases: an observational study using the American Collegeof Rheumatology nomenclature for neuropsychiatriclupus. Clinical and Experimental Rheumatology 2006;24 (6): 629-35. https://www.clinexprheumatol.org/a.asp?IDArchivio=72

  3. Germes Piña F. Corea gravídica. Reporte de un caso. GinecolObstet Mex 2009; 77 (3): 156-9. https://ginecologiayobstetricia.org.mx/download/2182

  4. Rengifo-Quintero LJ, Beltrán-Avendaño MA. ChoreGravidum: Case report and review of the literature. RevColomb Obstet Ginecol 2019; 70 (3): 189-94. https://doi.org/10.18597/rcog.3251

  5. Bhidayasiri R, Truong DD. Chorea and related disorders.Postgrad Med J 2004; 80 (947): 527-34. doi: 10.1136/pgmj.2004.019356

  6. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M,Ramsey-Goldman R, et al. 2019 European League AgainstRheumatism/American College of Rheumatology classificationcriteria for systemic lupus erythematosus. AnnRheum Dis 2019; 78 (9): 1151-59. doi: 10.1136/annrheumdis-2018-214819

  7. Molooghi K, Sheybani F, Naderi H, Mirfeizi Z, Morovatdar N,Baradaran A. Central nervous system infections in patientswith systemic lupus erythematosus: a systematic reviewand meta-analysis. Lupus Sci Med 2022; 9 (1): e000560.doi: 10.1136/lupus-2021-000560

  8. Petri M, Pregnancy and systemic lupus erythematosus.Best Pract Res Clin Obstet Gynaecol 2020; 64: 24-30.doi:10.1016/j.bpobgyn.2019.09.002

  9. Zhao X, Zhang J, Liang Y, Li J, Ding S, Wang Y, et al. Advancesin Drug Therapy for Systemic Lupus Erythematosus. CurrMed Chem 2021; 28 (6): 1251-68. doi: 10.2174/0929867327666200625150408

  10. Stanescu II, Calenic B, Dima A, Gugoasa LA, Balanescu E,Stefan-van Staden RI, et al. Salivary biomarkers of inflammationin systemic lupus erythematosus. Ann Anat 2018;219: 89-93. doi: 10.1016/j.aanat.2018.02.012

  11. Palma Dos Reis CR, Cardoso G, Carvalho C, Nogueira I, BorgesA, Serrano F. Prediction of Adverse Pregnancy Outcomesin Women with Systemic Lupus Erythematosus. ClinRev Allergy Immunol. 2020;59(3):287-294. doi: 10.1007/s12016-019-08762-9.

  12. Giambalvo S, Garaffoni C, Silvagni E, Furini F, Rizzo R,Govoni M, et al. Factors associated with fertility abnormalitiesin women with systemic lupus erythematosus:a systematic review and meta-analysis. Autoimmun Rev.2022;21(4):103038. doi: 10.1016/j.autrev.2022.103038.

  13. Nusbaum JS, Mirza I, Shum J, Freilich RW, Cohen RE, PillingerMH, et al. Sex Differences in Systemic Lupus Erythematosus:Epidemiology, Clinical Considerations, and DiseasePathogenesis. Mayo Clin Proc. 2020;95(2):384-394. doi:10.1016/j.mayocp.2019.09.012.

  14. Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH. LupusLow Disease Activity State Achievement Is Important forReducing Adverse Outcomes in Pregnant Patients With SystemicLupus Erythematosus. J Rheumatol. 2021;48(5):707-716. doi: 10.3899/jrheum.200802.

  15. Deng J, Li C, Kuang W, Han T, Zhang J, Tan X, et al. Clinicalcharacteristics of cerebral venous sinus thrombosis inchildhood-onset systemic lupus erythematosus patients:a single-centre study from China. Clin Exp Rheumatol.2021;39(6):1440-1445. doi: 10.55563/clinexprheumatol/kn8hco.

  16. Bundhun PK, Soogund MZ, Huang F. Impact of systemiclupus erythematosus on maternal and fetal outcomesfollowing pregnancy: A meta-analysis of studies publishedbetween years 2001-2016. J Autoimmun. 2017;79:17-27.doi: 10.1016/j.jaut.2017.02.009.

  17. Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movementdisorders in systemic lupus erythematosus and theantiphospholipid syndrome. J Neural Transm (Vienna).2013;120(11):1579-89. doi: 10.1007/s00702-013-1023-z.

  18. Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a studyof 41 patients. Neurology. 2007;69(7):644-54. doi:10.1212/01.wnl.0000267320.48939.d0.

  19. Galanaud D, Dormont D, Marsault C, Wechsler B, et al. BrainMRI in patients with past lupus-associated chorea. Stroke.

  20. 2000;31(12):3079-83. doi: 10.1161/01.str.31.12.3079-b.20. Menozzi E, Mulroy E, Akbarian-Tefaghi L, Bhatia KP, et al.Movement disorders in systemic autoimmune diseases: Clinicalspectrum, ancillary investigations, pathophysiologicalconsiderations. Parkinsonism Relat Disord. 2021;88:116-128. doi: 10.1016/j.parkreldis.2021.05.026.

  21. Cardoso F. Chorea gravidarum. Arch Neurol. 2002;59(5):868-70. doi: 10.1001/archneur.59.5.868.

  22. Torreggiani S, Torcoletti M, Cuoco F, Di Landro G, et al.Chorea, a little-known manifestation in systemic lupuserythematosus: short literature review and four casereports. Pediatr Rheumatol Online J. 2013;11(1):36. doi:10.1186/1546-0096-11-36.

  23. El-Sayed YY, Lu EJ, Genovese MC, Lambert RE, et al. Centralnervous system lupus and pregnancy: 11-year experienceat a single center. J Matern Fetal Neonatal Med. 2002Aug;12(2):99-103. doi: 10.1080/jmf.12.2.99.103.

  24. Sosa BO, Toral JAB. Identifying the aetiology of suddenacute abnormal involuntary movements in a primigravid.BMJ Case Rep. 2018;11(1):e227112. doi: 10.1136/bcr-2018-227112.

  25. Buyon JP, Cronstein BN, Morris M, Tanner M, et al.Serum complement values (C3 and C4) to differentiatebetween systemic lupus activity and pre-eclampsia.Am J Med. 1986;81(2):194-200. doi: 10.1016/0002-9343(86)90251-2.

  26. Bellos I, Pergialiotis V, Loutradis D, Daskalakis G. Theprognostic role of serum uric acid levels in preeclampsia:A meta-analysis. J Clin Hypertens. 2020;22(5):826-834.https://doi.org/10.1111/jch.13865

  27. Qazi U, Lam C, Karumanchi SA, Petri M. Soluble Fms-liketyrosine kinase associated with preeclampsia in pregnancyin systemic lupus erythematosus. J Rheumatol.2008;35(4):631-4. https://www.jrheum.org/content/jrheum/35/4/631.full.pdf

  28. Lynch AM, Murphy JR, Gibbs RS, Levine RJ, et al. The interrelationshipof complement-activation fragments andangiogenesis-related factors in early pregnancy and theirassociation with pre-eclampsia. BJOG. 2010;117(4):456-62.doi: 10.1111/j.1471-0528.2009.02473.x.

  29. Roberge S, Villa P, Nicolaides K, Giguère Y, et al. Earlyadministration of low-dose aspirin for the prevention ofpreterm and term preeclampsia: a systematic review andmeta-analysis. Fetal Diagn Ther. 2012;31(3):141-6. doi:10.1159/000336662.

  30. de Jesus GR, Rodrigues BC, Lacerda MI, Dos Santos FC, etal. Gestational outcomes in patients with neuropsychiatricsystemic lupus erythematosus. Lupus. 2017;26(5):537-542.doi: 10.1177/0961203317693929.

  31. Ainiala H, Hietaharju A, Loukkola J, Peltola J, et al. Validityof the new American College of Rheumatology criteriafor neuropsychiatric lupus syndromes: a populationbasedevaluation. Arthritis Rheum. 2001;45(5):419-23. doi: 10.1002/1529-0131(200110)45:5<419::aidart360>3.0.co;2-x.

  32. Dao KH, Bermas BL. Systemic Lupus Erythematosus Managementin Pregnancy. Int J Womens Health. 2022 Feb15;14:199-211. doi: 10.2147/IJWH.S282604.

  33. Marder W, Knight JS, Kaplan MJ, Somers EC, et al. Placentalhistology and neutrophil extracellular traps inlupus and pre-eclampsia pregnancies. Lupus Sci Med.2016;3(1):e000134. doi: 10.1136/lupus-2015-000134.

  34. Knight JS, Kaplan MJ. Lupus neutrophils: 'NET' gain inunderstanding lupus pathogenesis. Curr Opin Rheumatol.2012;24(5):441-50. doi: 10.1097/BOR.0b013e3283546703.

  35. Elkon KB, Wiedeman A. Type I IFN system in the developmentand manifestations of SLE. Curr Opin Rheumatol.2012;24(5):499-505. doi: 10.1097/BOR.0b013e3283562c3e.




2020     |     www.medigraphic.com